Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 479 results found since Jan 2013.

Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial
CONCLUSION: Results from this study highlight the benefits of adaptive emotion regulation in helping mitigate symptoms associated with breast cancer survivorship.PMID:37335884 | DOI:10.1093/abm/kaad032
Source: Annals of Behavioral Medicine - June 19, 2023 Category: Psychiatry & Psychology Authors: Megan E Renna Annelise A Madison Juan Peng Marcella Rosie Shrout Maryam Lustberg Bhuvaneswari Ramaswamy Robert Wesolowski Jeffrey B VanDeusen Nicole O Williams Sagar D Sardesai Anne M Noonan Raquel E Reinbolt Daniel G Stover Mathew Cherian William B Malar Source Type: research

PhRMA Report: Over 5400 Medicines in Development and 70% are First in Class
According to report released by PhRMA, companies have more than 5,400 medicines in development globally, and more than 70% of therapies in the pipeline are potentially first-in-class and could offer patients new treatment options, and a notable number of potential therapies target diseases with limited treatment options such as ALS and rare diseases.  A breakdown of their report offers insight into the various medicines in development for different diseases and populations.    Older Americans  America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditi...
Source: Policy and Medicine - April 24, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs

From routine dental visit to oral cancer…
CALIFORNIA MOM OF TWO HAS HALF OF HER TONGUE REMOVED AND A NEW ONE RECONSTRUCTED WITH FOREARMSomeone dies from oral cancer every hour of every day in the United States aloneEarly DETECTION – early cure: Oral Cancer Awareness Month in AprilLos Angeles, CA, February 11, 2014… A routine trip to the dentist saved the life of a California mom of two. The American Dental Association estimates that “60% of the US population visits a dentist every year, however less than 15% of them report having received an oral cancer screening.” Although the number of deaths each year from oral cancer is astoundingly large, it is highly...
Source: Dental Technology Blog - February 17, 2014 Category: Dentists Source Type: blogs

From routine dental visit to oral cancer… california mom of two has half of her tongue removed and a new one reconstructed with forearm
Someone dies from oral cancer every hour of every day in the United States aloneEarly DETECTION – early cure: Oral Cancer Awareness Month in AprilLos Angeles, CA, February 26, 2014… A routine trip to the dentist saved the life of a California mom of two. The American Dental Association estimates that “60% of the US population visits a dentist every year, however less than 15% of them report having received an oral cancer screening.” Although the number of deaths each year from oral cancer is astoundingly large, it is highly curable if diagnosed early. Early detection is a key factor in oral cancer care and a 90-sec...
Source: Dental Technology Blog - February 3, 2014 Category: Dentists Source Type: blogs

A Case Study of Oral Cancer Related to Human Papilloma Virus
ConclusionSymptoms of HPV‐related oropharyngeal cancer are elusive and make early diagnosis challenging. Although rare, the transmission and eventual development of HPV‐related oropharyngeal cancer is a valid concern for intimate partners. Providing education for nurses can increase awareness in women about the possibility of developing this disease and may lead to early detection and treatment. Increased awareness of the relationship between HPV and oropharyngeal cancer can also influence the choice for HPV vaccination.
Source: Journal of Obstetric, Gynecologic, and Neonatal Nursing - June 4, 2015 Category: Nursing Authors: Rose M. Scaffidi, Cheryle Eisele Tags: Women's Health Source Type: research

Statin Wars: Less-is-More versus Unlimited Medicine  
By SARAH JHA, MD It is the beauty of evidence-based medicine (EBM) that a scientist can at once be a Pope and a Galileo. His transmutation is as effortless as it is discretionary. If you think you’ve met Galileo – a rebel, a free thinker, a rocker of the establishment – the following week he is a Pope, castigating detractors, censoring critics, and celebrating uniformity. He changes by a roll of the dice. His change is decided by a quirk in hypothesis-testing known as statistical significance. If the p value is 0.051 he is Galileo, if the p value is 0.049 he becomes the cardinal. He is one day a raging skepti...
Source: The Health Care Blog - September 20, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs

What 1989 And The Golden Girls Tell Us About Medicine Today
Today, 1989 may be most associated with Taylor Swift: It is the album that won her a second Grammy for Album of the Year. Not only that, it happens to be the year Swift was born--such a long, long time ago! People under 35 have no personal memory of 1980s pop culture, which is ironic since Swift's album in part pays homage to it. In the real 1989 (no offense to Swift and the 10 co-producers who made the album), all sorts of revolutions took place: Mr. Gorbachev tore down that pesky wall, for example. America's greatest antagonist, the Soviet Union, collapsed in 1989. Brazil conducted its first democratic presidential ...
Source: Healthy Living - The Huffington Post - September 23, 2016 Category: Consumer Health News Source Type: news

How Long Does Shingles Last In The Elderly?
View Original Article Here: How Long Does Shingles Last In The Elderly? Shingles is a viral infection that follows a varicella-zoster infection, although it can take decades for symptoms of the secondary disease to emerge. The condition presents as a painful and blistering rash, but it is not life-threatening. According to the Center for Disease Control, there are nearly one million cases in the United States each year, and almost half of those cases are in older adults over age 60. Some people only see one instance of the illness, while others have recurring symptoms, but 30 percent of Americans will develop shingles at s...
Source: Shield My Senior - December 8, 2017 Category: Geriatrics Authors: Vin Tags: Senior Safety Source Type: blogs

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “While we contin...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s milestone mar...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Janss...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news